
Expectations are high for Novo Nordisk’s experimental once-weekly GLP-1 analogue semaglutide, which could potentially enter the market next year.
The candidate has already shown excellent results in a range of clinical trials in the so-called Sustain program and now, a new analysis of five of those studies shows that semaglutide is outperforming other drugs when it comes to reducing both weight and long-term blood glucose (HbA1c).
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app